Unity Biotechnology vs Cleara Biotech

Unity Biotechnology was the marquee publicly traded senolytics company; after its lead eye drug failed and it was delisted from Nasdaq, its board approved a plan of dissolution in 2025.

Longevity

Cleara Biotech

Utrecht spinout developing FOXO4-derived senolytic peptides to selectively destroy senescent cells in cancer and chronic disease.

For subscribers

Subscribe for the full comparison

Including Funding rounds + valuations, Founders + executives, Products + tech stack, Headcount + HQ, Status timeline, and Roster connections.

Already subscribed? Sign in →